Comparison of C-reactive protein levels between serum and plasma samples on long-term frozen storage after a 13.8 year interval: The JMS cohort study

Journal of Epidemiology

Volumn 17, Issue 4, 2007, Pages 120-124

  Ishikawa, Shizukiyo ^a   Kayaba, Kazunori ^b   Gotoh, Tadao ^a   Nakamura, Yosikazu ^a   Kario, Kazuomi ^a   Ito, Yoshihisa ^c   Kajii, Eiji ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b SAITAMA PREFECTURAL UNIVERSITY   (Japan)

^c ASAHIKAWA MEDICAL COLLEGE   (Japan)

Author keywords

C reactive protein; Japanese; Plasma; Stability; Time

Indexed keywords

C REACTIVE PROTEIN;

ARTICLE; BLOOD; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; COMPARATIVE STUDY; CRYOPRESERVATION; FEMALE; HEART INFARCTION; HUMAN; MALE; MIDDLE AGED; SENSITIVITY AND SPECIFICITY;

C-REACTIVE PROTEIN; CEREBROVASCULAR ACCIDENT; COHORT STUDIES; CRYOPRESERVATION; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; SENSITIVITY AND SPECIFICITY;

EID: 34547123551     PISSN: 09175040     EISSN: 13499092     Source Type: Journal    
DOI: 10.2188/jea.17.120     Document Type: Article

References (28)

1. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 973-9.
2. Danesh J, Muir J, Wong YK, Ward M, Gallimore JP, Pepys MB. Risk factors for coronary heart disease and acute-phase proteins. A population-based study. Eur Heart J 1999; 20: 954-9.
3. Koenig W, Sund M, Frohlich M, Fischer HG, Lowel H, Doring A, et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999; 99: 237-42.
4. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342: 836-43.
5. Rost NS, Wolf PA, Kase CS, Kelly-Hayes M, Silbershatz H, Massaro JM, et al. Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack: the Framingham study. Stroke 2001; 32: 2575-9.
6. Curb JD, Abbott RD, Rodriguez BL, Sakkinen P, Popper JS, Yano K, et al. C-reactive protein and the future risk of thromboembolic stroke in healthy men. Circulation 2003; 107: 2016-20.
7. Pai JK, Pischon T, Ma J, Manson JE, Hankinson SE, Joshipura. K, et al. Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med. 2004; 351: 2599-610.
8. Rutter MK, Meigs JB, Sullivan LM, D'Agostino RB, Sr., Wilson PW. C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study. Circulation 2004; 110: 380-5.
9. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004; 350:1387-97
10. Wakugawa Y, Kiyohara Y, Tanizaki Y, Kubo M, Ninomiya T, Hata J, et al. C-reactive protein and risk of first-ever ischemic and hemorrhagic stroke in a general Japanese population: the Hisayama Study. Stroke 2006; 37: 27-32.
11. Festa A, D'Agostino R, Jr., Howard G, Mykkanen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000; 102: 42-7.
12. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation 2003; 107: 391-7.
13. Lee WY, Park JS, Noh SY, Rhee EJ, Sung KC, Kim BS, et al. C-reactive protein concentrations are related to insulin resistance and metabolic syndrome as defined by the ATP III report. Int J Cardiol 2004; 97: 101-6.
14. Malik S, Wong ND, Franklin S, Pio J, Fairchild C, Chen R. Cardiovascular disease in U.S. patients with metabolic syndrome, diabetes, and elevated C-reactive protein. Diabetes Care 2005; 28: 690-3.
15. Ishikawa S, Kayaba K, Gotoh T, Nakamura Y, Kajii E. Metabolic syndrome and C-reactive protein in the general population. Circ J 2007; 71: 26-31.
16. Frohlich M, Imhof A, Berg G, Hutchinson WL, Pepys MB, Boeing H, et al. Association between C-reactive protein and features of the metabolic syndrome: a population-based study. Diabetes Care 2000; 23: 1835-9.
17. Han TS, Sattar N, Williams K, Gonzalez-Villalpando C, Lean ME, Haffner SM. Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study. Diabetes Care 2002; 25: 2016-21.
18. Laaksonen DE, Niskanen L, Nyyssonen K, Punnonen K, Tuomainen TP, Valkonen VP, et al. C-reactive protein and the development of the metabolic syndrome and diabetes in middle-aged men. Diabetologia 2004; 47: 1403-10.
19. Doi Y, Kiyohara Y, Kubo M, Ninomiya T, Wakugawa Y, Yonemoto K, et al. Elevated C-reactive protein is a predictor of the development of diabetes in a general Japanese population: the Hisayama Study. Diabetes Care 2005; 28: 2497-500.
20. Ridker PM, Wilson PW, Grundy SM. Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? Circulation 2004; 109: 2818-25.
21. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO, 3rd, Criqui M, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107: 499-511.
22. Macy EM, Hayes TE, Tracy RP. Variability in the measurement of C-reactive protein in healthy subjects: implications for reference intervals and epidemiological applications. Clin Chem 1997; 43: 52-8.
23. Aziz N, Fahey JL, Detels R, Butch AW. Analytical performance of a highly sensitive C-reactive protein-based immunoassay and the effects of laboratory variables on levels of protein in blood. Clin Diagn Lab Immunol 2003; 10: 652-7.
24. Ishikawa S, Gotoh T, Nago N, Kayaba K. The Jichi Medical School (JMS) Cohort Study: design, baseline data and standardized mortality ratios. J Epidemiol 2002; 12: 408-17.
25. Itoh Y, Ichihara K, Kanno T, Sugawara T, Ohkubo A, Hirabayashi Y, et al. Serum protein standardization project in Japan: evaluation of an IFCC reference material (RPPHS/CRM470) and establishment of reference intervals. J Clin Lab Anal 1997; 11: 39-44.
26. Yamada S, Gotoh T, Nakashima Y, Kayaba K, Ishikawa S, Nago N, et al. Distribution of serum C-reactive protein and its association with atherosclerotic risk factors in a Japanese population: Jichi Medical School Cohort Study. Am J Epidemiol 2001; 153: 1183-90.
27. Kayaba K, Ishikawa S, Gotoh T, Nago N, Kajii E, Nakamura Y, et al. Five-year intra-individual variability in C-reactive protein levels in a Japanese population-based study: the Jichi Medical School Cohort Study at Yamato, 1993-1998. Jpn Circ J 2000; 64: 303-8.
28. Nilsson TK, Boman K, Jansson J-H, Thogersen AM, Berggren M, Broberg A, et al. Comparison of soluble thrombomodulin, von Willebrand factor, tPA/ PAI-1 complex, and high-sensitivity CRP concentrations in serum, EDTA plasma, citrated plasma, and acidified citrated plasma (Stabilyte (TM)) stored at -70 degrees C for 8-11 years. Thromb Res. 2005; 116: 249-54.